Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

The Economic Times

Pfizer's Vitiligo Pill Shows Promise as Doctors Explain Why the Condition Is More Than Skin Deep

Pfizer says Phase 3 trials show Litfulo helped restore skin pigmentation in nonsegmental vitiligo, marking a promising advance in treatment.

Medical Daily

SpaceX Could Swing $204 Billion After Earnings

Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Benzinga Pro.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pregnant Patients Caught Between Two Vaccine Schedules Now Have Infant Hospitalization Numbers to Bring to the Appointment

ACOG and CDC guidance on pregnancy vaccines now differ. New research shows maternal RSV vaccination cut infant hospitalizations by about 68 percent.

Medical Daily

FDA Sets a Late-2026 Decision on Adding a PARP Inhibitor to Hormone Therapy for Advanced Prostate Cancer

FDA granted priority review to talazoparib plus enzalutamide for HRR-altered metastatic prostate cancer. A decision is expected in late 2026.

Medical Daily

Is Wall Street Bullish or Bearish on Pfizer Stock?

While Pfizer has trailed the broader market over the past year, Wall Street still sees room for upside and remains moderately optimistic about the company's prospects.

Barchart

GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'

Rep. Thomas Massie (R-Ky.) questioned Vice President JD Vance‘s silence after the Trump administration established billions for Pfizer Inc.‘s (NYSE:PFE) COVID-19 vaccine contracts for 2026 and 2027.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Only Available Syphilis Shot for Pregnancy Remains in Short Supply Through Early Next Year

Bicillin L-A, the only treatment for syphilis in pregnancy, is short until late 2027. What pregnant patients and clinicians should do now.

Medical Daily

Pfizer and the $200 Billion-Dollar Cardiovascular Market

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market.

International Business Times

When can a power company take your land for data center infrastructure?

The artificial intelligence boom in the United States is being matched by a data center building boom. There are more than 3,000 data centers in the U.S. and another 1,500 in development, according to a Pew Research Center analysis.

The Conversation

Here's What to Expect From Pfizer's Next Earnings Report

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

Barchart

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat

‘I have an inoperable brain tumour after having the contraceptive jab’

A study found women who used the contraceptive injection for at least a year are 5.6 times more likely to develop meningioma brain tumours

The Independent UK

Why companies are paying a premium for battle-tested CFOs—and Nike’s struggling turnaround shows what that costs

David Denton, Nike’s new CFO, is coming from Pfizer—underscoring how far companies will go to recruit proven top finance chiefs.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New York high-rise scare exposes the challenges of converting offices into housing

City officials have not determined what caused the columns to buckle but engineers believe the failure likely resulted from the added load

Fortune

'Failures happen during construction': Office-to-residential conversions are all over NYC, but failures usually get fixed before they get worse

An engineer says the failed columns at the former Pfizer HQ have nothing to do with steel material quality.

International Business Times UK

NYC Building's Columns 'Buckling', At Risk of Collapse; Mamdani Warns 'New Yorkers to Avoid the Area'

A former Pfizer building in Midtown Manhattan faces collapse risk due to structural issues, prompting evacuations of nearby buildings, including a school. Emergency crews are monitoring the situation closely.

International Business Times UK

Inside David Denton's Nike Pay Package: $7.25M Cash, $11.5M Stock Awards and a Turnaround Mandate

Nike's new CFO David Denton could earn up to $25.9m (£19.6m) in year one, including $7.25 million cash he must repay if he leaves within two years.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Women say contraceptive jab complications ‘life-changing’ at MSP meeting

Pfizer’s Depo-Provera has been previously linked to an increased risk of a type of brain tumour.

The Economic Times

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

International Business Times

The Drug Pricing Machine and Why Patients Keep Paying More

Roughly a third of American adults report difficulty paying for prescription drugs, and many are forced to skip doses, delay refills, or abandon treatment altogether.

Euronews

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.

Barchart

These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.

Medical Daily

The First Lyme Disease Vaccine in 24 Years Just Passed Its Pivotal Phase 3 Trial with 74 Percent Efficacy — and It Is for Children Too

Pfizer and Valneva announced Phase 3 VALOR trial results for Lyme disease vaccine PF-07307405 on March 23, 2026: 73.2–74.8% efficacy in ages 5 and older. Regulatory submissions planned for 2026. No Lyme vaccine has been available in the U.S. since 2002.

MarketBeat

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Parliament

715 stories

AstraZeneca

639 stories

Advanced Micro Devices

527 stories

GSK

422 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.